Phase 3 N=416 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks — 336; NA; 186 Days — p=0.0650
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=157 A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only — 6.3; 11.9 months
Phase 2 N=16 The Role Of Omega-3 Fatty Acids In Adolescent Depression
Depressive Disorder, Major
Primary: ACC Glx/Water — 19.21; 18.99; 19.28; 20.61 ratio * 10^-4
N/A N=5 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Accelerated Phase Chronic Myelogenous Leukemia · Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission
Primary: Death From Regimen Toxicity or Opportunistic Infection — 0 Participants
Phase 2 N=39 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Overall Survival — 25 Participants
N/A N=50 Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
Recurrent Melanoma
Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes
Phase 3 N=878 ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Per Independent Radiologic Review. — 2.6; 2.5 Months — p=0.195
Phase 2 N=6 Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia
Acute Myeloid Leukemia in Remission · de Novo Myelodysplastic Syndrome · Fanconi Anemia
Primary: Number of Patients Who Engraft at Each Dose of TBI Used — 5; 1 Participants
N/A N=150 Facilitating EndotracheaL Intubation by Laryngoscopy Technique and Apneic Oxygenation Within the Intensive Care Unit: The FELLOW Study
Respiratory Failure
Primary: Successful First Attempt at Endotracheal Intubation (Defined by Confirmed Placement of an Endotracheal Tube in the Trachea During First Laryngoscopy Attempt) After…
Phase 2 N=45 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
B-cell Chronic Lymphocytic Leukemia · Nodal Marginal Zone B-cell Lymphoma · Recurrent Adult Burkitt Lymphoma
Primary: Treatment Related Mortality (TRM) — 16 percent
Phase 2 N=33 Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Adverse Events (AE's) — 25; 2; 8; 3 participants
Phase 3 N=24 Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
Osteoarthritis
Primary: Allograft Stability — 0
Phase 4 N=39 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults
Bipolar Disorder · Alcohol Abuse
Primary: Drinks Per Day — -1.4; -2.4 Drinks per day
N/A N=19 PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
Borderline Personality Disorder
Primary: Change in Brain Metabolism From Baseline to Eight Weeks as Seen in PET Scan — 11.5 Standard uptake value — p=<0.05
Phase 2 N=98 Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
Influenza A · Influenza B
Primary: Time to Normalization of Respiratory Status (Primary Efficacy Population) — 7; 28 days — p=0.069